CY1114898T1 - Σταθερα σκευασματα πρωτεϊνης - Google Patents

Σταθερα σκευασματα πρωτεϊνης

Info

Publication number
CY1114898T1
CY1114898T1 CY20141100029T CY141100029T CY1114898T1 CY 1114898 T1 CY1114898 T1 CY 1114898T1 CY 20141100029 T CY20141100029 T CY 20141100029T CY 141100029 T CY141100029 T CY 141100029T CY 1114898 T1 CY1114898 T1 CY 1114898T1
Authority
CY
Cyprus
Prior art keywords
protein preparations
stable protein
routes
stable
lyophilized
Prior art date
Application number
CY20141100029T
Other languages
English (en)
Inventor
Manisha M Dali
Charles E Dahlheim
Sunita Borsadia
Vijay H Naringrekar
Rajesh B Gandhi
Manoj Nerurkar
Original Assignee
Bristol-Myers Squibb Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP06846683.8A external-priority patent/EP1962886B2/en
Application filed by Bristol-Myers Squibb Company filed Critical Bristol-Myers Squibb Company
Publication of CY1114898T1 publication Critical patent/CY1114898T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται γενικά με σταθερά σκευάσματα που περιλαμβάνουν CTLA4Ig μόρια, μεταξύ αυτών λυοφιλοποιημένα, και υγρά σκευάσματα για χορήγηση μέσω διαφόρων οδών όπως, για παράδειγμα, μέσω ενδοφλέβιας (IV) και υποδόριας (SC) οδού για την αγωγή παθήσεων του ανοσοποιητικού συστήματος και την επαγωγή ανοχής.
CY20141100029T 2005-12-20 2014-01-14 Σταθερα σκευασματα πρωτεϊνης CY1114898T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75215005A 2005-12-20 2005-12-20
EP06846683.8A EP1962886B2 (en) 2005-12-20 2006-12-19 Stable protein formulations

Publications (1)

Publication Number Publication Date
CY1114898T1 true CY1114898T1 (el) 2016-12-14

Family

ID=58464048

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100029T CY1114898T1 (el) 2005-12-20 2014-01-14 Σταθερα σκευασματα πρωτεϊνης

Country Status (2)

Country Link
CY (1) CY1114898T1 (el)
SI (1) SI1962886T2 (el)

Also Published As

Publication number Publication date
SI1962886T1 (sl) 2014-01-31
SI1962886T2 (sl) 2022-05-31

Similar Documents

Publication Publication Date Title
SG153832A1 (en) Stable protein formulations
CY1118467T1 (el) Σκευασματα αντισωματων και πρωτεϊνων υψηλης συγκεντρωσης
CY1118373T1 (el) Υψηλης συγκεντρωσης υγρες μορφοποιησεις anti-tnfa αντισωματος
CY1124844T1 (el) Φαρμακευτικο σκευασμα αντισωματος
CY1119563T1 (el) Βελτιστοποιηση αντισωματων που δεσμευουν το γονιδιο-3 ενεργοποιησης λεμφοκυτταρων (lag-3), και χρησεις εξ' αυτων
BR112021005769A2 (pt) proteínas de ligação a dll3 e métodos de uso
CY1117387T1 (el) ΜΟΝΟΚΛΩΝΙΚΑ ΑΝΤΙΣΩΜΑΤΑ Ν-11 ΔΙΑΣΠΑΣΜΕΝΟΥ β-ΑΜΥΛΟΕΙΔΟΥΣ, ΣΥΝΘΕΣΕΙΣ, ΜΕΘΟΔΟΙ ΚΑΙ ΧΡΗΣΕΙΣ
EA201290123A1 (ru) Продукты слияния и конъюгаты лекарственных средств с увеличенным периодом полувыведения
EP4249064A3 (en) Novel fusion protein specific for cd137 and pd-l1
CY1115414T1 (el) Παραγωγα υποκατεστημενου 1-3-διφαινυλπροπανιου, παρασκευες και χρησεις αυτων
CY1107628T1 (el) Ανθρωπινα ctla-4 αντισωματα και χρησεις αυτων
CY1110530T1 (el) Ανοσοσφαιρινες που εξουδετερωνουν το nogoa για τη θεραπεια νευρολογικων ασθενειων
BR112012022223A2 (pt) formulações de proteína concentrada e usos das mesmas
TW200801042A (en) Anti-CTLA-4 antibody and CpG-motif-containing synthetic oligodeoxynucleotide combination therapy for cancer treatment
MX2021010039A (es) Novedosas proteinas de fusion especificas para cd137 y gpc3.
DK1272515T3 (da) Immunregulator
DK2280721T3 (da) Indoleamin-2, 3-dioxygenasebaseret immunterapi
BRPI0314373B8 (pt) produto imunogênico estável para a indução de anticorpos contra uma ou várias proteínas antigênicas em um indivíduo, composições farmacêutica, imunogênica e de vacina e processo de preparação de um produto imunogênico
MX2021005134A (es) Nuevos conjugados citostaticos con ligandos de integrina.
CY1114724T1 (el) Ανασυνδυασμενες πρωτεϊνες ελαστασης και μεθοδοι βιομηχανικης κατασκευης και χρηση αυτων
BR112014017141A2 (pt) método de tratamento de diabetes usando-se apolipoproteína a-iv não glicosilada
MX2020009150A (es) Anfifilos de cpg y usos de los mismos.
MX337358B (es) Conjugados de disorazoles y sus derivados con moleculas de union con celulas, nuevos derivados de disorazol, procesos de fabricacion y usos de los mismos.
CY1114898T1 (el) Σταθερα σκευασματα πρωτεϊνης
DE60325838D1 (de) Imidazoquinolinamine als adjuvantien für hiv dna vakzine